Cancer pain

Cancer Neurology In Clinical Practice: Neurologic Complications of Cancer and Its Treatment: Second Edition

Volumn , Issue , 2008, Pages 113-128

  Mercadante, Sebastiano ^a  

^a LA MADDALENA CANCER CENTER   (Italy)

Author keywords

bone pain; headache; neuropathic pain; opioids; pain

Indexed keywords

EID: 77649179401     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-59745-412-4_8     Document Type: Chapter

References (41)

1. Cleeland CS, Gonin R, Hatfield AK et al. Pain and its treatment in outpatients with metastatic cancer. N Engl J Med 1994;330:592-596.
2. Von Roenn JH, Cleeland CS, Gonin R et al. Physician attitudes and practice in cancer pain management. Ann Int Med 1993;119: 121-126.
3. Besson JM. The neurobiology of pain. Lancet 1999;353:1610-1615.
4. Dickenson AH. Pharmacology of pain transmission and control. In: Pain 1996: An Updated Review, JN Campbell ed. Seattle: IASP Press, 1996;113-121.
5. Cervero F, Laird JMA. Visceral pain. Lancet 1999;353:2145-2148.
6. Portenoy RK, Conn M. Cancer pain syndromes. In: Cancer Pain, Assessment and Management, Bruera E, Portenoy RK, eds. New York: Cambridge University Press, 2003;38-50.
7. Portenoy RK, Foley KM, Inturrisi CE. The nature of opioid responsiveness and its implications for neuropathic pain: new hypotheses derived from studies of opioid infusions. Pain 1990;43:273-286.
8. Caraceni A, Brunelli C, Martini C et al. Cancer pain assessment in clinical trials: a review of the literature (1999-2002). J Pain Symptom Manage. 2005;29:507-519.
9. Serlin RC, Mendoza TR, Nakamura Y et al. When is cancer pain mild, moderate, or severe? Grading pain severity by its interference with function. Pain. 1995;61:277-284.
10. Mercadante S, Villari P, Ferrera P et al. Opioid-induced or pain relief-reduced symptoms in advanced cancer patients? Eur J Pain. 2006;10:153-159.
11. World Health Organization. Cancer Pain Relief and Palliative Care. Geneva: WHO 1990.
12. Jadad AR, Browman GP. The WHO analgesic ladder for cancer pain management. JAMA 1995;274:1870-1873.
13. Mercadante S. Pain treatment and outcome in advanced cancer patients followed at home. Cancer 1999, 85:1849-1858.
14. Eisenberg E, Berkey C, Carr DB et al. Efficacy and safety of nonsteroidal antinflammatory drugs for cancer pain: a meta-analysis. J Clin Oncol 1994;12:2756-2765.
15. Mercadante S, Fulfaro F, Casuccio A. A randomised controlled study on the use of anti-inflammatory drugs in patients with cancer on morphine therapy: effect on dose-escalation and pharmacoeconomic analysis. Eur J Cancer 2002;38:1358-1363.
16. Mercadante S, Porzio G, Ferrera P et al. Low morphine doses in opioid-naive cancer patients with pain. J Pain Symptom Manage 2006;31:242-247.
17. Mercadante S, Arcuri E. Opioids and renal function. J Pain. 2004;5:2-19.
18. Hanks GW and Expert Working Group of the Research Network of the EAPC. Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer 2001;84:587-593.
19. Mercadante S, Villari P, Ferrera P et al. Rapid titration with intravenous morphine for severe cancer pain and immediate oral conversion. Cancer 2002;95:203-208.
20. Nelson KA, Glare PA, Walsh D et al. A prospective, within-patient, crossover study of continuous intravenous and subcutaneous morphine for chronic cancer pain. J Pain Symptom Manage. 1997;13:262-267.
21. Mercadante S, Fulfaro F. Alternatives to oral morphine in cancer pain. Oncology. 1999;13:215-225.
22. Glare P, Walsh D, Sheehan D. The adverse effects of morphine: a prospective survey of common symptoms during repeated dosing for chronic cancer pain. Am J Hosp Palliat Care. 2006;23:229-235
23. Cherny N, Ripamonti C, Pereira J et al. Strategies to manage the adverse effects of oral morphine: an evidence-based report. J Clin Oncol. 2001;19:2542-2554.
24. Mercadante S. Opioid rotation in cancer pain, rationale and clinical aspects. Cancer 1999;86:1856-1866.
25. Bruera E, Pereira J, Watanabe S et al. Opioid rotation in patients with cancer pain: a retrospective comparison of dose ratios between methadone, hydromorphone, and morphine. Cancer 1996;78;852-857.
26. Lawlor P, Turner K, Hanson J et al. Dose ratio between morphine and methadone in patients with cancer pain: a retrospective study. Cancer 1998;82:1167-1173.
27. Ripamonti C, Groff L, Brunelli C et al. Switching from morphine to oral methadone in treating cancer pain: what is the equianalgesic dose ratio? J Clin Oncol, 1998;16:3216-3221.
28. Morley JS, Makin MK. Comments on Ripamonti et al. Pain, 1997;70:109-115.
29. Mercadante S, Casuccio A, Calderone L. Rapid switching from morphine to methadone in cancer patients with poor response to morphine. J Clin Oncol 1999;17:3307-3312.
30. Donner B, Zenz M, Tryba M et al. Direct conversion from oral morphine to transdermal fentanyl: a multicenter study in patients with cancer pain. Pain 1996;64:527-534.
31. Portenoy RK, Hagen NA. Breakthrough pain: definition, prevalence, and characteristics. Pain 1990;41:273-281.
32. Portenoy RK, Payne R, Coluzzi P et al. Oral transmucosal fentanyl citrate (OTFC) for the treatment of breakthrough pain in cancer patients: a controlled-dose titration study. Pain 1999;79:303-312.
33. Christie JM, Simmonds M, Patt R et al. Dose-titration, multicenter study of oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients using transdermal fentanyl for persistent pain. J Clin Oncol 1998;16:3238-3245.
34. Farrar JT, Cleary J, Rauck R et al. Oral transmucosal fentanyl citrate: randomised, double-blinded, placebo-controlled trial for treatment of breakthrough pain in cancer patients. J Natl Cancer Inst 1998;90:611-616.
35. Portenoy RK, Rowe G. Adjuvant analgesic drugs. In: Cancer Pain, Assessment and Management, Bruera E, Portenoy RK, eds. New York: Cambridge University Press 2003;188-198.
36. Caraceni A, Zecca E, Bonezzi C et al. Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group. J Clin Oncol. 2004;22:2909-2917.
37. Mercadante S. Malignant bone pain: physiopathology, assessment and treatment. Pain, 1997;69:1-18.
38. Mercadante S. Problems of long-term spinal opioid treatment in advanced cancer patients. Pain 1999;79:1-13.
39. Tasker RR. Neurosurgical and neuroaugmentative intervention. In: Patt RB, ed. Cancer Pain. Philadelphia: JB Lippincott Co, 1993;471-500.
40. Plancarte R, de Leon-Casasola OA, El-Helaly M et al. Neurolytic superior hypogastric plexus block for chronic pelvic pain associated with cancer. Reg Anesth, 1997;22:562-568.
41. Mercadante S, Nicosia F. Celiac plexus block: a reappraisal. Reg Anesth Pain Med 1998;21:407-413.